Evidence map›Paper›PMID 35613023›Full record

ReviewThe New England journal of medicine2022

Gliflozins in the Management of Cardiovascular Disease.

Eugene Braunwald

3 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 124 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06012266 phase2unknown statusstarted 2024, after this paper: background citation

Dose Rationale for Dapagliflozin and Empagliflozin in Paediatric Heart Failure: a Phase II.a Pharmacokinetics, Ease-of-swallow, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

Ran2024Enrolled12Registered outcomes19Posted comparisons0ConditionsHeart FailureArmsDapagliflozin Tablet, Empagliflozin Tablets
PMID 35083827PMID 35948644PMID 33708503PMID 33637556PMID 32865377PMID 32000955PMID 31535829PMID 29958420PMID 27812385PMID 26785826PMID 24216246PMID 22633303other papers from this trial
Open the trial in the graph
NCT06113900 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Assessment of Safety and Efficacy of Sodium Glucose Co-transporter 2 Inhibitors Among Lupus Nephritis Patients

TypeinterventionalSponsorAin Shams UniversityRan2023 to 2025Enrolled50ConditionsLupus NephritisArmsDapagliflozin 10mg Tab orally once daily
NCT06643442 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Repurposing Empagliflozin for Duchenne Muscular Dystrophy - Associated Cardiomyopathy: a Pharmacokinetics, Safety and Proof-of-concept Study Among Children 6-18 Years of Age

TypeinterventionalSponsorSebastiano LavaRan2025 to 2027Enrolled12ConditionsDMD-associated Dilated CardiomyopathyArmsEmpagliflozin Tablets
3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Long-term effects of ipragliflozin on blood pressure in patients with type 2 diabetes: insights from the randomized PROTECT trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Trial
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Eugene BraunwaldFrom the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and the Department of Medicine, Harvard Medical School, Boston.ORCID 0000-0002-3472-626X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cardiovascular DiseasesSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID35613023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.